The growing health burden of cancer: a global epidemiological overview.-Cost of Cancer Care: Health expenditures and economic impact -- Innovation in R&D: An answer to cancer -- The Evaluation of Benefits, Harms and Costs of Cancer Screening -- Oncology from a HTA and health economic perspective -- Heterogeneous recommendations for oncology products among different HTA systems: a comparative assessment -- Outcomes in oncology: clinical vs. patient-reported outcome performance measures -- The value of patient-reported outcome in health economic decision making: a changing landscape in oncology -- Approaches to capture value in oncology -- Orphan durgs in oncology -- Recent developments in health economic modeling of cancer therapies -- Drug pricing and value in oncology -- Pharmaceutical price regulation of cancer treatments -- Regulatory and evidence requirements and the changing landscape in regulation for marketing authorization -- Looking for Willingness to Pay (WTP) Threshold for a QALY in oncology -- Equity and patient access to innovative cancer treatments. .

This book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society's willingness to pay.